Credo's Pullback: How It Became AI's Nerve System

Credo reported record Q1 FY2026 revenue of $223.1 million, up 274% year-over-year, with non-GAAP gross margins expanding to 67.6%.
C&EN

Discovery of Anthranilic Acid Derivatives as Difluoromethylornithine Adjunct Agents That ...

Laboratory of Pathology, Center for Cancer Research, 10 Center Drive, Building 10, Room 2N106, Bethesda, Maryland 20892-1500, United States Article Views are the COUNTER-compliant sum of full text ...